Korea's First Homegrown COVID-19 Treatment
Zuellig Pharma announced on Feb. 22 that it has signed an agreement with Celltrion Group to distribute Korea’s first COVID-19 treatment Regkinona.
Regkinona is the first homegrown COVID-19 treatment to receive conditional approval from the Korean Ministry of Food and Drug Safety.
The Korea Centers for Disease Control and Prevention said it will provide Regkinona to COVID-19 patients aged 60 or older or with underlying diseases or pneumonia among patients who do not need oxygen treatment and are within seven days of symptom onset.
Zuellig Pharma is planning to distribute Regkinona using cold chain (extremely low temperature distribution) systems. The drug should be maintained at 2 to 8 degrees Celsius for transportation and storage.
Zuellig Pharma has refrigeration and freezing storage facilities whose combined areas total about 10,000 square meters. It has a state-of-the-art system to transport medicines using specialized trucks equipped with thermostats and thermometers, and track the locations of products during delivery.